Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Pegcetacoplan in PNH Patients with Extra-Vascular Hemolysis Under Anti-C5: The Real-Life Experience of the National French Reference Center

Flore Sicre de Fontbrune, Edouard Forcade, Louis Terriou, Alice Garnier, Vincent Alcazer, Nicolas Daguindau, Lynda Maafa, Isabelle Brindel, Regis Peffault de Latour, Sylvie Chevret

Blood (2024) 144 (Supplement 1): 1321.

https://doi.org/10.1182/blood-2024-199472

Published: 2024

Journal Articles

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Franck E. Nicolini, Elisabetta Abruzzese, Gabrielle Roth-Guepin, Rami Abi-Tayeh, Vincent Alcazer, Sandrine Hayette, Stéphane Morisset, Françoise Huguet, Miriam Iezza, Fausto Castagnetti, Delphine Rea

Blood (2023) 142 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2023-178326

Published: 2023

Journal Articles

Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients: Predictive Models Developed on a Nationwide Clinical and Claim Database

Jules Chassetuillier, Meriem Benmerad, Pierre-Louis Lecoq, Romain Favier, Matthieu Trancart, Sandrine Hayette, Vincent Alcazer, Christophe Bouvier, Julien Bollard, Audrey Lajoinie, Franck E. Nicolini

Blood (2023) 142 (Supplement 1): 6369.

https://doi.org/10.1182/blood-2023-179970

Published: 2023

Journal Articles

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.

Franck E. Nicolini, Vincent Alcazer, Pascale Cony-Makhoul, Stéphanie Dulucq, Sandrine Hayette, Stéphane Morisset, Rachel Parat, Christophe Bouvier, Gabriel Etienne

Blood (2022) 140 (Supplement 1): 3918–3919.

https://doi.org/10.1182/blood-2022-163376

Published: 2022

Journal Articles

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Franck E. Nicolini, Vincent Alcazer, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Stephane Morisset, Christophe Bouvier, Francois-Xavier Mahon, Gabriel Etienne, Delphine Rea

Blood (2021) 138 (Supplement 1): 2552.

https://doi.org/10.1182/blood-2021-146722

Published: 2021

Journal Articles

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Franck E Nicolini, MDPhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD, Stephanie Dulucq, PharmD, PhD, Sandrine Hayette, PhD, Stephane Morisset, BioStat, Jean-Michel Cayuela, PharmD, PhD, Marie-Pierre Fort, PhD, Christophe Bouvier, CRA, Clemence Deteix-Santana, MD, Etienne Lengline, MD, Delphine Rea, MDPhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139921

Published: 2020

Journal Articles

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Blood (2018) 132 (Supplement 1): 48.

https://doi.org/10.1182/blood-2018-99-113058

Published: 2018

Journal Articles

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Franck Emmanuel Nicolini, MD PhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD PhD, Stephanie Dulucq, PhD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Villa, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2018) 132 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2018-99-113044

Published: 2018

Journal Articles

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Gaelle Fossard, MD, Vincent Alcazer, MD, Marie Balsat, MD, Helene Labussiere-Wallet, MD, Stephane Morisset, Stat, Mohamad Sobh, Isabelle Tigaud, MD, Pierre Sujobert, MD PhD, Mauricette Michallet, MD PhD, Franck Emmanuel Nicolini, MD PhD

Blood (2017) 130 (Supplement 1): 2900.

https://doi.org/10.1182/blood.V130.Suppl_1.2900.2900

Published: 2017

Journal Articles

Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML

Franck Emmanuel Nicolini, MD PhD, Delphine Rea, MD, Vincent Alcazer, MD, Francoise Huguet, MD, Laurence Legros, MD PhD, Gaelle Fossard, MD, Elodie Grockowiak, PhD, Stephane Morisset, Stat, Pierre Sujobert, MD PhD, Mohamad Sobh, Mauricette Michallet, MD PhD, Francois Parant, PharmD, Marie-Claude Gagnieu, PharmD

Blood (2017) 130 (Supplement 1): 2901.

https://doi.org/10.1182/blood.V130.Suppl_1.2901.2901

Published: 2017

Journal Articles

Characterisation of Molecular Relapse Profiles after Tyrosine Kinase Inhibitor Cessation in Patients Eligible for Treatment-Free Remission Strategies in Chronic Phase CML

Franck E Nicolini, MD PhD, Vincent Alcazer, MD, Stephanie Dulucq, PharmD, PhD, Marie Balsat, MD, Helene Labussiere, MD, Helene Lequeu, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Pierre Sujobert, MD PhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2016) 128 (22): 1893.

https://doi.org/10.1182/blood.V128.22.1893.1893

Published: 2016

Journal Articles

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients

Franck E. Nicolini, MD PhD, Gaelle Fossard, MD, Valerie Coiteux, MD, Viviane Dubruille, MD, Vincent Alcazer, MD, Mohamad Sobh, PharmD, Pierre Mouchel, MD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD, Agnes Guerci, MD PhD

Blood (2016) 128 (22): 1894.

https://doi.org/10.1182/blood.V128.22.1894.1894

Published: 2016

Journal Articles

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

Franck E. Nicolini, MD PhD, Marie Balsat, MD, Maud Lekieffre, MD, Vincent Alcazer, MD, Hélène Labussière-wallet, MD, Sarah Huet, PharmD, PhD, Sandrine Hayette, Stéphanie Dulucq, PharmD, PhD, Stéphane Morisset, Stat, Jeremy Ruby, CRA, Isabelle Tigaud, MD, Marie-Pierre Fort, CRA, Mael Heiblig, MD, Rémi Chapelon, CRA, Madeleine Etienne, CRA, Mohamad Sobh, PharmD, Francois-Xavier Mahon, MD PhD Professor, Mauricette Michallet, MD PhD, Gabriel Etienne, MD PhD

Blood (2015) 126 (23): 2774.

https://doi.org/10.1182/blood.V126.23.2774.2774

Published: 2015

NARROW

Efficacy and Safety of Pegcetacoplan in PNH Patients with Extra-Vascular Hemolysis Under Anti-C5: The Real-Life Experience of the National French Reference Center

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients: Predictive Models Developed on a Nationwide Clinical and Claim Database

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML

Characterisation of Molecular Relapse Profiles after Tyrosine Kinase Inhibitor Cessation in Patients Eligible for Treatment-Free Remission Strategies in Chronic Phase CML

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only